Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 November 2007, Vol. 110, No. 10, pp. 3561-3563.
Prepublished online as a Blood First Edition Paper on August 2, 2007; DOI 10.1182/blood-2007-07-099481.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2007-07-099481v1
110/10/3561    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanchorawala, V.
Right arrow Articles by Seldin, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanchorawala, V.
Right arrow Articles by Seldin, D. C.
Related Collections
Right arrow Immunobiology
Right arrow Neoplasia
Right arrow Free Research Articles
Right arrow Brief Reports
Right arrow Clinical Trials and Observations
Right arrowRelated Article in Blood Online
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CLINICAL TRIALS AND OBSERVATIONS

Brief Report

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

Vaishali Sanchorawala1,2, Martha Skinner2, Karen Quillen1,3, Kathleen T. Finn1,2, Gheorghe Doros4, and David C. Seldin1,2

1 Stem Cell Transplantation Program of the Section of Hematology-Oncology, 2 Amyloid Treatment and Research Program, Department of Medicine, 3 Department of Pathology and Laboratory Medicine, Boston University School of Medicine; and 4 Department of Biostatistics, Boston University School of Public Health, MA

Long-term survival and outcome were determined for 80 patients with immunoglobulin light chain (AL) amyloidosis treated with high-dose melphalan and stem cell transplantation (HDM/SCT) more than 10 years ago. Seventeen (21%) patients died within the first year of treatment, of treatment-related complications (14%) or progressive disease (8%). Of the 63 surviving evaluable patients at one year, 32 (51%) achieved a complete hematologic response (CR). For all 80 patients, the median survival was 57 months (4.75 yrs). The median survival exceeds 10 years for patients achieving a CR after HDM/SCT, compared with 50 months for those not achieving a CR (P < .001). In conclusion, HDM/SCT leads to durable remissions and prolonged survival, particularly for those patients who achieve a hematologic CR.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Amyloidosis: graviores morbos, asperis remedii
Jayesh Mehta
Blood 2007 110: 3490-3491. [Full Text] [PDF]





click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020